Looking to broaden its use of artificial intelligence to help lock down its R&D work, Johnson & Johnson’s biotech unit Janssen has penned a new deal with AI specialist nference.
The multiyear deal, financial details of which were not disclosed, will see the Big Pharma “leverage the nference artificial intelligence (AI) platform to create a unified data science-powered connective fabric across the Janssen R&D organization.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,